BioXcel Therapeutics Enters Material Definitive Agreement
Ticker: BTAI · Form: 8-K · Filed: Jul 17, 2024 · CIK: 1720893
Sentiment: neutral
Topics: material-agreement, filing
TL;DR
BioXcel Therapeutics just signed a big deal, filing an 8-K to confirm.
AI Summary
BioXcel Therapeutics, Inc. announced on July 11, 2024, that it entered into a material definitive agreement. The company, incorporated in Delaware with its principal executive offices in New Haven, CT, filed this Form 8-K to report this significant event.
Why It Matters
This filing indicates a significant development for BioXcel Therapeutics, likely involving a new partnership, acquisition, or licensing deal that could impact its future operations and stock value.
Risk Assessment
Risk Level: medium — Entering a material definitive agreement can introduce new risks related to the terms of the agreement, potential integration challenges, or changes in strategic direction.
Key Players & Entities
- BioXcel Therapeutics, Inc. (company) — Registrant
- July 11, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- New Haven, CT (location) — Address of principal executive offices
FAQ
What is the nature of the material definitive agreement entered into by BioXcel Therapeutics?
The filing does not specify the exact nature of the material definitive agreement, only that one was entered into on July 11, 2024.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on July 11, 2024.
Where are BioXcel Therapeutics' principal executive offices located?
BioXcel Therapeutics' principal executive offices are located at 555 Long Wharf Drive, New Haven, CT 06511.
What is BioXcel Therapeutics' state of incorporation?
BioXcel Therapeutics is incorporated in Delaware.
What is the SEC file number for BioXcel Therapeutics?
The SEC file number for BioXcel Therapeutics is 001-38410.
Filing Stats: 449 words · 2 min read · ~1 pages · Grade level 11.8 · Accepted 2024-07-17 16:41:41
Key Financial Figures
- $0.001 B — ch registered Common Stock, par value $0.001 BTAI The Nasdaq Capital Market Indic
Filing Documents
- tm2419377d2_8k.htm (8-K) — 23KB
- 0001104659-24-080571.txt ( ) — 190KB
- btai-20240711.xsd (EX-101.SCH) — 3KB
- btai-20240711_lab.xml (EX-101.LAB) — 33KB
- btai-20240711_pre.xml (EX-101.PRE) — 22KB
- tm2419377d2_8k_htm.xml (XML) — 3KB
01. Entry into a Material Definitive Agreement
Item 1.01. Entry into a Material Definitive Agreement. On July 11, 2024, BioXcel Therapeutics, Inc. (the "Company") entered into Amendment No. 1 (the "Amendment") to the Commercial Supply Agreement, dated as of April 1, 2022, with ARx, LLC ("ARx"). The Amendment reduces the specified minimum annual payment payable by the Company to ARx over the next three years starting in 2024 and, thereafter, for a specified interval, provides for minimum annual payments to the extent that the Company receives approval of a supplemental new drug application (sNDA) or a new drug application (NDA) from the U.S. Food and Drug Administration for enumerated indications.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: July 17, 2024 BIOXCEL THERAPEUTICS, INC. /s/ Richard Steinhart By: Richard Steinhart Title: Chief Financial Officer